In prostate cancer, CXCR4 expression is associated with higher tumor grade, and the use of a neutralizing antibody to CXCR4 limited the extent of bone metastases and growth of intraosseous prostate cancer cells after intratibial injections [41,42]. This evidence concerns the gene CXCR4 and neoplasm.